Company Management

Gryphon Bio

Biotechnology Research 611 Gateway Blvd 7 employees

Employees: 7
Contacts: 2
Emails: 2
Phones: 1

gryphonbio.com LinkedIn Crunchbase

Gryphon Bio Overview

Headquarters: 611 Gateway Blvd
Website: gryphonbio.com
Industry: Biotechnology Research
Employees: 7
Founded: 2018
Funding: 6.7M
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

traumatic brain injury multiple sclerosis epilepsy Alzheimer's disease chronic traumatic encephalopathy temporal biomarkers brain medicine therapeutic bioconjugate antibody

About Gryphon Bio

Gryphon Bio is an early-stage company created to harness our co-founders' discovery of unexpected waves of 1000s of brain molecules in the blood as novel therapeutic targets and temporal blood biomarkers (brain-specific proteins with blood levels that change over time like waves in the ocean). They made these discoveries over more than 20 years of “brain proteomic” research, the large-scale measurement of proteins in the brain. Mission: To develop and market the first diagnostic-powered therapeutics for brain health. Vision: To pioneer diagnostic-powered therapeutics to improve the lives of patients.

Gryphon Bio Contact Details

People in AeroLeads: 4
With contact data: 2
Email contacts: 2; 50.0% coverage
Phone contacts: 1; 25.0% coverage

Gryphon Bio Org Chart

Sample employees and titles

Name	Title	Location	Contact
Dr. William E. Haskins	CEO & Founder at Owl Therapeutics		View
Christopher Hanson			View
Kevin K.w. Wang	Interim Director, Neuroscience	Gainesville Metropolitan Area, United States	Email Phone
Tony Delizza	Medical Devices	San Francisco, California, United States	Email